Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
Trevi Therapeutics to Participate in Upcoming May Events
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
What's Going On With Trevi Therapeutics Stock?
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
SG Americas Securities LLC Has $1.56 Million Stock Position in Trevi Therapeutics, Inc. $TRVI
Trevi Therapeutics to Participate in Upcoming Events
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts
Head-To-Head Review: Trevi Therapeutics (NASDAQ:TRVI) vs. DNAPrint Genomics (OTCMKTS:DNAG)
Trevi Therapeutics Q4 Earnings Call Highlights
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
Trevi Therapeutics to Participate in Upcoming March Conferences
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up on Strong Earnings
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Trevi Therapeutics to Participate in Upcoming September Conferences
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
Trevi Therapeutics to Participate in Upcoming August Conferences
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm
Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI)
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares